Juliana Schwaab
Heidelberg University
93 Papers
160 Citations
Juliana Schwaab is an academic researcher from Heidelberg University. The author has contributed to research in topics: Systemic mastocytosis & Medicine. The author has an hindex of 20, co-authored 59 publications.
Chat about Author
Papers
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
Peter Valent,Amy D. Klion,Florence Roufosse,Dagmar Simon,Georgia Metzgeroth,Kristin M. Leiferman,Juliana Schwaab,Joseph H. Butterfield,Wolfgang R. Sperr,Karl Sotlar,Peter Vandenberghe,Gregor Hoermann,Torsten Haferlach,Richard Moriggl,Tracy I. George,Cem Akin,Bruce S. Bochner,Jason Gotlib,Andreas Reiter,Hans-Peter Horny,Michel Arock,Hans-Uwe Simon,Gerald J. Gleich +22 more
TL;DR: A panel of experts representing the relevant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and pathology, met and discussed new markers and concepts as well as refinements in definitions, criteria and classifications of HE and HES to assist in the diagnosis and management of patients with HE.
76
Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event
Mohamad Jawhar,Juliana Schwaab,Susanne Schnittger,Karl Sotlar,Hans-Peter Horny,Georgia Metzgeroth,Sven Schneider,Nadine Muller,Nicole Naumann,Christoph Walz,Torsten Haferlach,Peter Valent,Wolf-Karsten Hofmann,Nicholas C.P. Cross,Alice Fabarius,Andreas Reiter +15 more
TL;DR: The mutation profile of single-cell-derived CFU-GM colonies - by using Sanger sequencing - is explored in 19 KIT D816V+ SM patients to gain more insight into clonal evolution of myeloid progenitors in indolent and advanced SM with or without AHNMD.
75
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Juliana Schwaab,Nicole Naumann,Johannes Luebke,Mohamad Jawhar,Tim C. P. Somervaille,Mark S. Williams,Rebecca Frewin,Philipp J. Jost,Felix S. Lichtenegger,Paul La Rosée,Nicola Storch,Torsten Haferlach,Hans-Peter Horny,Alice Fabarius,Claudia Haferlach,Andreas Burchert,Wolf-Karsten Hofmann,Nicholas C.P. Cross,Nicholas C.P. Cross,Andreas Hochhaus,Andreas Reiter,Georgia Metzgeroth +21 more
TL;DR: Responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6‐ABL1 positive patients.
60
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance
Juliana Schwaab,Roland Umbach,Georgia Metzgeroth,Nicole Naumann,Mohamad Jawhar,Karl Sotlar,Hans-Peter Horny,Timo Gaiser,Wolf-Karsten Hofmann,Susanne Schnittger,Nicholas C.P. Cross,Alice Fabarius,Andreas Reiter +12 more
TL;DR: There is a clear prognostic and therapeutic rationale for detection of KIT D816V and JAK2 V617F in the diagnostic work up of eosinophilia.
58
Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
Katharina Blatt,Sabine Cerny-Reiterer,Juliana Schwaab,Karl Sotlar,Gregor Eisenwort,Gabriele Stefanzl,Gregor Hoermann,Matthias Mayerhofer,Mathias Schneeweiss,Sylvia Knapp,Thomas Rülicke,Emir Hadzijusufovic,Karin Bauer,Dubravka Smiljkovic,Michael Willmann,Andreas Reiter,Hans-Peter Horny,Peter Valent +17 more
TL;DR: Brentuximab-vedotin and the KIT D816V-targeting drug PKC412 produced synergistic growth-inhibitory effects in MCPV-1.1 cells, and CD30 is a promising new drug target for patients with CD30(+) advanced SM.
52